TY  - JOUR
U1  - Wissenschaftlicher Artikel
A1  - Schommers, Philipp
A1  - Kim, Dae Sung
A1  - Schlotz, Maike
A1  - Kreer, Christoph
A1  - Eggeling, Ralf
A1  - Hake, Anna
A1  - Stecher, Melanie
A1  - Park, Juyeon
A1  - Radford, Caelan E.
A1  - Dingens, Adam S.
A1  - Ercanoglu, Meryem S.
A1  - Gruell, Henning
A1  - Odidika, Stanley
A1  - Dahlhaus, Marten
A1  - Gieselmann, Lutz
A1  - Ahmadov, Elvin
A1  - Lawong, Rene Y.
A1  - Heger, Eva
A1  - Knops, Elena
A1  - Wyen, Christoph
A1  - Kümmerle, Tim
A1  - Römer, Katja
A1  - Scholten, Stefan
A1  - Wolf, Timo
A1  - Stephan, Christoph
A1  - Suárez, Isabelle
A1  - Raju, Nagarajan
A1  - Adhikari, Anurag
A1  - Esser, Stefan
A1  - Streeck, Hendrik
A1  - Duerr, Ralf
A1  - Nanfack, Aubin J.
A1  - Zolla-Pazner, Susan
A1  - Geldmacher, Christof
A1  - Geisenberger, Otto
A1  - Kroidl, Arne
A1  - William, Wiston
A1  - Maganga, Lucas
A1  - Ntinginya, Nyanda Elias
A1  - Georgiev, Ivelin S.
A1  - Vehreschild, Jörg J.
A1  - Hoelscher, Michael
A1  - Fätkenheuer, Gerd
A1  - Lavinder, Jason J.
A1  - Bloom, Jesse D.
A1  - Seaman, Michael S.
A1  - Lehmann, Clara
A1  - Pfeifer, Nico
A1  - Georgiou, George
A1  - Klein, Florian
T1  - Dynamics and durability of HIV-1 neutralization are determined by viral replication
JF  - Nature Medicine
N2  - Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from HIV-1 neutralizers-persons with HIV-1 who naturally develop broad and potent nAbs-can inform about the dynamics and durability of nAb responses in humans, knowledge which is crucial for the design of future HIV-1 vaccine regimens. To address this, we assessed HIV-1-neutralizing immunoglobulin G (IgG) from 2,354 persons with HIV-1 on or off antiretroviral therapy (ART). Infection with non-clade B viruses, CD4+ T cell counts <200 µl-1, being off ART and a longer time off ART were independent predictors of a more potent and broad neutralization. In longitudinal analyses, we found nAb half-lives of 9.3 and 16.9 years in individuals with no- or low-level viremia, respectively, and 4.0 years in persons who newly initiated ART. Finally, in a potent HIV-1 neutralizer, we identified lower fractions of serum nAbs and of nAb-encoding memory B cells after ART initiation, suggesting that a decreasing neutralizing serum activity after antigen withdrawal is due to lower levels of nAbs. These results collectively show that HIV-1-neutralizing responses can persist for several years, even at low antigen levels, suggesting that an HIV-1 vaccine may elicit a durable nAb response.
KW  - Antibodies, Neutralizing
KW  - HIV Infections
KW  - HIV-1
KW  - Virus Replication
KW  - HIV Antibodies
KW  - Humans
KW  - AIDS Vaccines
Y1  - 2023
SN  - 1078-8956
SS  - 1078-8956
U6  - https://doi.org/10.1038/s41591-023-02582-3
DO  - https://doi.org/10.1038/s41591-023-02582-3
PM  - 37957379
VL  - 29
IS  - 11
SP  - 2763
EP  - 2774
S1  - 12
PB  - Springer Nature
ER  -